Clear Search

Showing 19 results for “systemic lupus erythematosus” published 2023.

May 2023

Belimumab Versus Anifrolumab in Adults with Systemic Lupus Erythematosus: An Indirect Comparison of Clinical Response at 52 Weeks

Lupus Sci. Med 2023;10:e000907 doi 10.1136/lupus-2023-000907

This retrospective study by Neupane, et al. compared belimumab and anifrolumab efficacy at 52 weeks in SLE patients. It concluded that belimumab and anifrolumab have equal efficacy, but further studies would be needed for specific patient demographics.

more…

April 2023

Does Remission in Systemic Lupus Erythematosus According to the 2021 DORIS Definition Match the Treating Rheumatologist’s Judgment?

Rheumatology (Oxford) 2023;63(1):72–8 doi: 10.1093/rheumatology/kead159

Assessment on agreement between the 2021 DORIS and physician-judged lupus activity finds the 2021 DORIS remission to be an achievable target in clinical practice, with substantial agreement between the DORIS definition and physician-judged remission.

more…

March 2023
February 2023

Lupus Low Disease Activity State Attainment in the Phase 3 TULIP Trials of Anifrolumab in Active Systemic Lupus Erythematosus

Ann Rheum Dis. 2023. doi: 10.1136/ard-2022-222748

Post-hoc anaylsis of TULIP trials shows that, compared with placebo, anifrolumab treatment was associated with earlier, more frequent, and more prolonged and sustained lupus low disease activity state (LLDAS).

more…